Natural Plant Compounds Block Neuropeptide-Triggered Inflammation in Mast Cells

What the researchers found

Substance P and neurotensin both induced dose-dependent serotonin release from rat peritoneal mast cells, while neuromedin-N did not. Two natural α,β-unsaturated lactones — dehydroleucodine and xanthatin — inhibited this neuropeptide-induced serotonin release, while a third compound (3-benzyloxymethyl-5H-furan-2-one) did not.

Notably, dehydroleucodine and xanthatin showed higher inhibitory potency than the reference anti-allergy compounds ketotifen and sodium chromoglycate when mast cells were pretreated before neuropeptide exposure. This represents the first evidence that these compounds can block neuropeptide-specific mast cell activation, distinct from their previously known effects on other degranulation pathways.

Why it matters

Neurogenic inflammation — where nerves and immune cells amplify each other's signals — drives conditions like chronic pain, migraines, and irritable bowel syndrome. Current treatments for mast cell activation are limited in effectiveness. Finding natural compounds that specifically block the neuropeptide-mast cell interaction could lead to new therapies for these difficult-to-treat conditions.

How the study worked

In vitro study using rat peritoneal mast cells. Cells were exposed to neuropeptides (substance P, neurotensin, neuromedin-N) at various concentrations to induce serotonin release. The three lactone compounds were tested as pretreatments and compared against reference anti-allergy drugs (ketotifen and sodium chromoglycate). Serotonin release was measured as the primary outcome of mast cell degranulation.

What this study cannot tell us

This was an in vitro study using isolated rat mast cells, which may not fully represent the complex in vivo environment of neurogenic inflammation. The compounds were not tested in animal pain models. Human mast cell responses may differ from rat peritoneal mast cells. Pharmacokinetic properties (absorption, metabolism, toxicity) of these lactones were not assessed.

How to read the evidence

This is an in vitro cell biology study providing the first evidence for this specific mechanism. While the comparative data against reference drugs is compelling, the lack of in vivo validation keeps this at a preclinical evidence level.

When this study was published

Published in 2020, this study provides foundational evidence for a relatively new approach to targeting neurogenic inflammation through neuropeptide-mast cell interactions.

The bigger picture

This study bridges neuroscience and immunology, addressing the critical neuro-immune crosstalk that underlies many chronic inflammatory and pain conditions. By targeting the specific mechanism by which neuropeptides activate mast cells, these compounds could represent a more precise approach to managing neurogenic inflammation compared to broad anti-inflammatory drugs.

Questions still open

• Do dehydroleucodine and xanthatin reduce neurogenic inflammation and pain in animal models?
• What is the molecular mechanism by which these lactones specifically block neuropeptide-induced degranulation?
• Could these compounds be developed into topical or oral treatments for neuropathic pain conditions?

Common questions

Read the original research

Natural α,β-unsaturated lactones inhibit neuropeptide-induced mast cell activation in an in vitro model of neurogenic inflammation.

Inflammation research : official journal of the European Histamine Research Society ... [et al.], 69(10), 1039-1051

Citation

Coll, Roberto Carlos; Vargas, Patricia María; Mariani, María Laura; Penissi, Alicia Beatriz. (2020). Natural α,β-unsaturated lactones inhibit neuropeptide-induced mast cell activation in an in vitro model of neurogenic inflammation.. Inflammation research : official journal of the European Histamine Research Society ... [et al.], 69(10), 1039-1051. https://doi.org/10.1007/s00011-020-01380-8